Case reports of etanercept in inflammatory dermatoses

被引:59
作者
Norman, R
Greenberg, RG
Jackson, JM
机构
[1] Univ Louisville, Div Dermatol, Louisville, KY 40202 USA
[2] Nova SE Univ, Ft Lauderdale, FL 33314 USA
[3] E Bay Psoriasis Treatment Ctr, San Ramon, CA USA
关键词
D O I
10.1016/j.jaad.2005.11.1090
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Skin disfigurations and pruritus can pose severe threats to quality of life, and treatment options for patients with recalcitrant diseases are limited. Tumor necrosis factor a, a proinflammatory cytokine, appears to play a central role in mediating the symptoms of many skin disorders. We report cases in which etanercept (Enbrel; Immunex Corp, Thousand Oaks, Calif), a tumor necrosis factor a antagonist that is approved for the treatment of moderate to severe psoriasis, was administered to ameliorate the symptoms of acute and chronic dermatologic conditions, including Hailey-Hailey disease, severe psoriasis, dermatomyositis, and subacute cutaneous lupus erythematosus. Treatment with etanercept substantially improved the clinical symptoms and quality of life in these patients, and may offer a therapeutic option for some patients with severe skin disorders.
引用
收藏
页码:S139 / S142
页数:4
相关论文
共 10 条
[1]   The genetics of psoriasis, psoriatic arthritis and atopic dermatitis [J].
Bowcock, AM ;
Cookson, WOCM .
HUMAN MOLECULAR GENETICS, 2004, 13 :R43-R55
[2]  
Cush JJ, 2004, CLIN EXP RHEUMATOL, V22, pS141
[3]  
Goffe B, 2004, Skin Therapy Lett, V9, P1
[4]   Comparative study of the impact of chronic urticaria, psoriasis and atopic dermatitis on the quality of life [J].
Grob, JJ ;
Revuz, J ;
Ortonne, JP ;
Auquier, P ;
Lorette, G .
BRITISH JOURNAL OF DERMATOLOGY, 2005, 152 (02) :289-295
[5]  
*IMM CORP, 2005, ENBR ET FULL PRESCR
[6]   Social anxiety and disfigurement: The moderating effects of fear of negative evaluation and past experience [J].
Kent, G ;
Keohane, S .
BRITISH JOURNAL OF CLINICAL PSYCHOLOGY, 2001, 40 :23-34
[7]   Psoriasis treatment: traditional therapy [J].
Lebwohl, M ;
Ting, PT ;
Koo, JYM .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 :83-86
[8]   Cutaneous manifestations of systemic diseases [J].
Robson, KJ ;
Piette, WW .
MEDICAL CLINICS OF NORTH AMERICA, 1998, 82 (06) :1359-+
[9]   The use of systemic immune moderators in dermatology: An update [J].
Stern, DK ;
Tripp, JM ;
Ho, VC ;
Lebwohl, M .
DERMATOLOGIC CLINICS, 2005, 23 (02) :259-+
[10]  
Vizcarra Cora, 2003, J Infus Nurs, V26, P319, DOI 10.1097/00129804-200309000-00008